[1] |
Erjavec Z, Kluin⁃Nelemans H, Verweij PE. Trends in invasive fungal infections, with emphasis on invasive aspergillosis[J]. Clin Microbiol Infect, 2009,15(7):625⁃633. doi: 10.1111/j.1469⁃0691.2009.02929.x.<br />
|
[2] |
Abad A, Fernández⁃Molina JV, Bikandi J, et al. What makes Aspergillus fumigatus a successful pathogen? Genes and molecules involved in invasive aspergillosis[J]. Rev Iberoam Micol, 2010,27(4):155⁃182. doi: 10.1016/j.riam.2010.10.003.<br />
|
[3] |
Sales⁃Campos H, Tonani L, Cardoso CR, et al. The immune interplay between the host and the pathogen in Aspergillus fumigatus lung infection[J]. Biomed Res Int, 2013,2013:693023. doi: 10.1155/2013/693023.<br />
|
[4] |
Lemoine S, Jaron B, Tabka S, et al. Dectin⁃1 activation unlocks IL12A and reveals the TH1 potency of neonatal dendritic cells[J]. J Allergy Clin Immunol, 2015,136(5):1355⁃1368.e1⁃15. doi: 10.1016/j.jaci.2015.02.030.<br />
|
[5] |
Rosentul DC, Plantinga TS, Oosting M, et al. Genetic variation in the dectin⁃1/CARD9 recognition pathway and susceptibility to candidemia[J]. J Infect Dis, 2011,204(7):1138⁃1145. doi: 10.1093/infdis/jir458.<br />
|
[6] |
Roilides E, Dimitriadou⁃Georgiadou A, Sein T, et al. Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus[J]. Infect Immun, 1998,66(12):5999⁃6003.<br />
|
[7] |
Filler SG, Yeaman MR, Sheppard DC. Tumor necrosis factor inhibition and invasive fungal infections[J]. Clin Infect Dis, 2005,41 Suppl 3:S208⁃212. doi: 10.1086/430000.<br />
|
[8] |
Tsiodras S, Samonis G, Boumpas DT, et al. Fungal infections complicating tumor necrosis factor alpha blockade therapy[J]. Mayo Clin Proc, 2008,83(2):181⁃194.<br />
|
[9] |
Zhang HJ, Qu JM, Shao CZ, et al. Aspergillus fumigatus conidia upregulates NOD2 protein both in vitro and in vivo[J]. Acta Pharmacol Sin, 2008,29(10):1202⁃1208. doi: 10.1111/j.1745⁃7254.2008.00860.x.<br />
|
[10] |
Gantner BN, Simmons RM, Canavera SJ, et al. Collaborative induction of inflammatory responses by dectin⁃1 and Toll⁃like receptor 2[J]. J Exp Med, 2003,197(9):1107⁃1117. doi: 10.1084/jem.20021787.<br />
|
[11] |
Jameel NM, Thirunavukkarasu C, Wu T, et al. p38⁃MAPK⁃ and caspase⁃3⁃mediated superoxide⁃induced apoptosis of rat hepatic stellate cells: reversal by retinoic acid[J]. J Cell Physiol, 2009,218(1):157⁃166. doi: 10.1002/jcp.21581.<br />
|
[12] |
del BBI, Nebreda AR. Roles of p38 MAPKs in invasion and metastasis[J]. Biochem Soc Trans, 2012,40(1):79⁃84. doi: 10.1042/BST20110676.<br />
|
[13] |
Sun Y, Chen H, Ma S, et al. Administration of SB203580, a p38 MAPK inhibitor, reduced the of MMP9, and relieved neurologic severity in the experimental autoimmune neuritis (EAN) in rats[J]. Neurochem Res, 2015,40(7):1410⁃1420. doi: 10.1007/s11064⁃015⁃1608⁃z.<br />
|
[14] |
Meng A, Wang B, Zhang X, et al. Additive suppression of LPS⁃induced IL⁃10 and TNF⁃α by pre⁃treatment of dexamethasone and SB203580 in a murine alveolar macrophage cell line (MH⁃S)[J]. Inflammation, 2015,38(3):1260⁃1266. doi: 10.1007/s10753⁃014⁃0093⁃x.<br />
|